Addressing the knowledge gaps surrounding AMR infections in neonatal sepsis
While progress in reducing the rate of child mortality since the launch of the Millennium Development Goals in 1990 has been promising, improvements in reducing neonatal mortality have been far slower. Infections in the neonatal period are one of the major contributors to an ongoing high rate of neonatal morbidity and mortality worldwide. In an era of increasing antimicrobial resistance (AMR), the burden of infections caused by multidrug-resistant (MDR) bacteria resistant to the current WHO empirical therapeutic guidelines is resulting in a persistently unacceptably high rate of perinatal and infant mortality globally.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.